Advertisement
Screener

Generate Biomedicines, Inc. (GENB) Net Income (Loss) Available to Common Stockholders, Basic

2.8 / 5 stars · 68/120 Roast Me

Generate Biomedicines, Inc. Net Income (Loss) Available to Common Stockholders, Basic

Generate Biomedicines, Inc. (GENB) reported Net Income (Loss) Available to Common Stockholders, Basic of -$67.25 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.

Financial Statements › Income Statement › Net Income

us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic · last filed 2026-08-06

  • Generate Biomedicines, Inc. net income (loss) available to common stockholders, basic for the quarter ending 2026-06-30 was -$67.25M.
  • Generate Biomedicines, Inc. net income (loss) available to common stockholders, basic for the quarter ending 2026-03-31 was -$69.19M.
  • Generate Biomedicines, Inc. net income (loss) available to common stockholders, basic for the quarter ending 2025-06-30 was -$64.02M.
  • Generate Biomedicines, Inc. net income (loss) available to common stockholders, basic for the quarter ending 2025-03-31 was -$53.28M.
Period endNet Income (Loss) Available to Common Stockholders, Basic 3 monthNet Income (Loss) Available to Common Stockholders, Basic 6 month
2026-06-30-$67.25M
10-Q · filed 2026-08-06
-$136.45M
10-Q · filed 2026-08-06
2026-03-31-$69.19M
10-Q · filed 2026-05-07
2025-06-30-$64.02M
10-Q · filed 2026-08-06
-$117.30M
10-Q · filed 2026-08-06
2025-03-31-$53.28M
10-Q · filed 2026-05-07

Similar stocks

Stock NameCountryMarket CapPE Ratio
PERRIGO Co plc (PRGO)Ireland$2.038B-0.79
NEKTAR THERAPEUTICS (NKTR)United States$2.026B-9.05
UroGen Pharma Ltd. (URGN)$2.015B-18.42
Trevi Therapeutics, Inc. (TRVI)United States$2.091B-51.93
Nuvation Bio Inc. (NUVB)United States$2.007B-13.12
PALVELLA THERAPEUTICS, INC. (PVLA)United States$2.105B-35.55
Braveheart Bio, Inc. (BRVE)United States$2.106B
Bausch Health Companies Inc. (BHC)$2.113B-1.68
Biohaven Ltd. (BHVN)United States$1.990B-3.83
AGIOS PHARMACEUTICALS, INC. (AGIO)United States$1.962B-5.38